A case of aspergillus myocarditis associated with septic shock

Rouby, Y.; Combourieu, E.; Perrier-Gros-Claude, Jean-David; Saccharin, C.; Huerre, Michel

doi:10.1016/s0163-4453(98)92262-9

Cited by 11 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few data exist on circulatory dysfunction and the development of shock in patients with IPA. However, some case reports mention the development of circulatory failure in these patients [24,25]. The neutropenic rats with IPA in our model developed a circulatory failure, as demonstrated by a marked decrease in arterial blood pressure on day 7 after fungal inoculation.…”

Section: Discussionmentioning

confidence: 87%

Pathophysiology of unilateral pulmonary aspergillosis in an experimental rat model

Becker¹,

Marie²,

Fens³

et al. 2006

Med Mycol

View full text Add to dashboard Cite

Because little is known about the pathophysiology of invasive pulmonary aspergillosis (IPA), we examined changes in pulmonary and general physiology during this disease in an animal model. In a model of fatal left-sided IPA, 19 persistently neutropenic rats were monitored for clinical signs including body temperature, body weight and respiratory distress. A separate group of nine rats with IPA was used for measurements of arterial blood pressure, arterial O2 and CO2 pressure, lung compliance and surfactant function. Body temperature and body weight decreased, whereas respiratory distress increased during progression of the disease. Compared to uninfected controls, in rats with IPA arterial blood pressure and lung compliance were significantly lower, and left lung minimal surface tension was significantly higher. Right lung surfactant function was not affected. Arterial O2 and CO2 pressures were not different between rats with IPA and uninfected controls. Infection with Aspergillus fumigatus in neutropenic rats resulted in hypothermia, body weight loss and respiratory distress. Loss of left lung function was probably compensated by the uninfected right lung, even in a late stage of the disease. Circulatory failure was a major feature in the terminal phase of the infection.

show abstract

Section: Discussionmentioning

confidence: 87%

Pathophysiology of unilateral pulmonary aspergillosis in an experimental rat model

Becker¹,

Marie²,

Fens³

et al. 2006

Med Mycol

View full text Add to dashboard Cite

show abstract

“…Most pediatric infections are caused by Aspergillus fumigatus and Aspergillus flavus; occasional reports implicate Aspergillus nidans and Aspergillus terrus as the cause of pediatric infections (5,6). Invasive aspergillosis is predominantly a disease of immunocompromised patients, but there are rare reports of invasive aspergillosis in immunocompetent patients as well (1,2). Well-established risk factors for invasive aspergillosis include underlying lung disease, prolonged neutropenia, immunosuppressive therapy, corticosteroid therapy, hematopoietic stem cell transplantation, and graft vs. host disease (7).…”

Section: Discussionmentioning

confidence: 99%

“…I nvasive aspergillosis, which has very high morbidity and mortality rates, is extremely rare in immunocompetent patients, with only a few cases described in the literature (1,2). We report a 9-yr-old boy who developed acute onset heart failure and complete heart block due to invasive aspergillosis.…”

mentioning

confidence: 93%

Invasive nosocomial aspergillosis associated with heart failure and complete heart block following recovery from dengue shock syndrome

Kohli

Sahu²,

Lodha³

et al. 2007

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…Consequently in most reported cases it is dif cult to determine to what extent the myocarditis contributed to the patient's death (3); however, a review of the world literature failed to reveal survival of patients with either Aspergillus pancarditis or isolated myocarditis. In any case, Aspergillus myocarditis is sometimes responsible for severe symptoms, with associated electrocardiographic and echographic changes, and may result in fatality after a very short clinical course (3,11,12). We believe that our patient almost certainly died of Aspergillus-induced acute myocarditis and secondary heart failure, in view of the clinical, laboratory and necropsy ndings and the absence of other clear etiological alternatives.…”

Section: Discussionmentioning

confidence: 76%

Fatal Aspergillus Myocarditis Following Short-term Corticosteroid Therapy for Chronic Obstructive Pulmonary Disease

M¹,

J²,

M³

et al. 2002

Scandinavian Journal of Infectious Diseases

View full text Add to dashboard Cite

A 58-y-old man with chronic obstructive pulmonary disease (COPD) was admitted for treatment of an acute exacerbation of his illness. The patient's condition initially improved after therapy with oxygen, bronchodilators, antibiotic and methylprednisolone (40 mg every 8 h) was started. Soon afterwards, however, the patient's clinical status deteriorated and he died on the fifth hospital day. Post-mortem examination revealed unsuspected, isolated fungal myocarditis. The fungus was later identified as Aspergillus by indirect immunofluorescence. To our knowledge, this is the first case of fatal Aspergillus myocarditis related to short-term (< 1 week) steroid therapy in a COPD patient. We believe that this case provides further evidence to support the possibility of life-threatening infections in COPD patients who receive even a short course of corticosteroid treatment.

show abstract

A case of aspergillus myocarditis associated with septic shock

Cited by 11 publications

References 18 publications

Pathophysiology of unilateral pulmonary aspergillosis in an experimental rat model

Pathophysiology of unilateral pulmonary aspergillosis in an experimental rat model

Invasive nosocomial aspergillosis associated with heart failure and complete heart block following recovery from dengue shock syndrome

Fatal Aspergillus Myocarditis Following Short-term Corticosteroid Therapy for Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About